Finding God has been the answer for Olivia Anderson, 46, a Norfolkan who has been fighting an ongoing battle with lymphoma ...

The company said that ZAMTO Cell is designed to target both CD19 and CD20, which could improve treatment efficacy.

ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...

Azercabtagene zapreleucel has been granted fast track designation from the FDA for the treatment of diffuse large B-cell ...

Wojciech Jurczak, MD, PhD, ​​discusses the future of B-cell lymphoma therapy, with a focus on Bruton's tyrosine kinase ...

Dozens from the Newtown community and beyond came together to honor Reed Intermediate School teacher Julie Shull at two ...

The author of the ‘Leonard List’ that highlights emerging hematologic research to be presented at annual ASH meetings is also ...

Lyell Immunopharma’s (LYEL) jumped over 8% on Friday as investors’ interest surged. Despite posting unimpressive Q4 results a ...

FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large ...

Data incorporated for this study were collected from 9 centers in the UK focused on third-line and beyond chimeric antigen ...

Innate Pharma continues its slow rollout of promising clinical candidates, with 2025 set for key milestones. Read more about ...

Last November, results from the MITIGATE trial made headlines at ACR Convergence 2024 with positive phase 3 trial data for inebilizumab, an IgG1 monoclonal antibody targeting CD19, in patients with ...